0:00. Seo Jung-jin Celltrion Inc. Cheongwon-gu Cheongju-si His marketing subsidiary, Celltrion Healthcare, went […] A Celltrion spokesman said CEOs at each of the group affiliates will lead them independently, as has been done under Seo's leadership. 1. Tweet. 100% Upvoted. SHARE THIS ARTICLE. 32 was effective in both the U.K. and South African variants, and the company will launch clinical trials in South Africa to develop it as a cocktail treatment. After Celltrion Chairman Seo Jung-jin stepped down from his post at the biopharmaceutical giant, attention is being paid to the future shape of the company's leadership. Celltrion's founder, Jung Jin Seo, is the second-richest person in South Korea. Of them, antibody No. Tweet. After this, the group plans to merge Celltrion Holdings and Celltrion Healthcare Holdings by the end of 2021, and will pursue the merger between Celltrion, Celltrion Healthcare and Celltrion Pharm. Apart from strategic partners, Celltrion will gradually hand over more sales control to its marketing and distribution arm Celltrion Healthcare by trimming down its sales partners in order to put the plan in motion for most countries by no later than July, he said. Seo said that under normal circumstances, the process would take about 18 months, though, given the emergency in South Korea, they plan to … Jung-jin Seo Chairman of Celltrion Group Jung-jin Seo is the founder and Chairman of Celltrion Group, a leading Korean biopharmaceutical company. 1 comment. Seo will hold an honorary chairman title without salary. Jung Jin Seo, Honorary Chairman, Celltrion Group Celltrion Healthcare is now heading towards the world At launch, we did not know what we were getting ourselves into. PyeongChang Peace Forum 2021 CH1_Day1. What frustrated Celltrion founder Seo Jung-jin 16 years ago was the lack of ambition he saw in his younger coworkers at the now-defunct Daewoo Motors. The former Daewoo executive recalled how miserable the plan was at a speech last month. By Yoojung Lee Seo Jung-jin used to borrow money from loan sharks, pledging his organs to get much needed funds for his upstart drugmaker. report. Horror film 'Spiral' soars in local box office, Kwon Yu-ri and Jung Il-woo's drama 'Bossam' surges in rating, 'Well, that's it': 96-year-old DJ bids farewell in Hong Kong, Singer-songwriter Heize's new EP to come out on May 20, Outgoing Celltrion Chairman Seo Jung-jin speaks during a biotechnology industry conference in Incheon, Nov. 18. Seo established Celltrion in 2002 and began to research the resources for production facilities for biopharmaceuticals. share. Following his departure, he will also officially step down from other posts with Celltrion Group companies at each of their annual general meetings set for next month. Seo's retirement came 19 years after he established Celltrion, which is now Korea’s 10th largest company by market cap. Also, the plan will enable a smoother succession of Seo's stakes in the group to his sons. Seo’s vacancy at Celltrion Group is being filled by his two sons, who are in their mid-30s. Biosimilars are used to treat chronic and severe illnesses. After Celltrion Chairman Seo Jung-jin stepped down from his post at the biopharmac­eutical giant, attention is being paid to the future shape of the company’s leadership. hide. 82 2 Sandan-ro Ochang-eup Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. The Company develops and produces biosimilar products, ethical drugs, over the counter drugs, and other related products. The group has yet to announce plans on its future chairmanship, but it is anticipated that the next chairman will be appointed at the shareholders meeting. Seo Jung-jin Celltrion will attempt to develop a Covid-19 vaccine if no other Korean company succeeds in doing so, according to Chairman Seo Jung-jin on Thursday. LISTEN TO ARTICLE. Gov't considers allowing hiring of foreign housekeepers, Belgian envoy's wife to avoid punishment for assault thanks to diplomatic immunity, Vaccine, chips, North Korea on agenda for Seoul-Washington summit, Samsung to leverage chip investment for 'vaccine swap', [INTERVIEW] P4G Seoul Summit to highlight Korea's commitment, efforts toward climate change, Israel pounds Gaza, flattens building housing AP and Al Jazeera, [Test Drive] On the road with 'pinnacle of luxury' Mercedes-Benz S-Class, [ANALYSIS] SK hynix unlikely to acquire GlobalFoundries, New cases in 600s for 2nd day amid vaccination campaign. Sort by. Post. Play. Settings. A Chinese restaurant, they said, was the way to make a living after Daewoo went bankrupt. Seo Jung-jin is cofounder of Celltrion, a biopharmaceutical firm that makes drugs to treat cancer, influenza and rheumatoid arthritis, among others. He is Celltrion board chairman and an internal director of Celltrion Healthcare and Celltrion Pharm. Celltrion's market capitalisation is now US$23.1 billion (S$30.8 billion), making Mr Seo the second richest man in South Korea. "The goal is launching an isolated clinical trial in South Africa and completing Phase 2 studies in the next six months," Seo said. Seo Jung-jin used to borrow money from loan sharks, pledging his organs to get much needed funds for his upstart drugmaker. As Celltrion Group Chairman Seo Jung-jin has said earlier, the development of these solutions is driven … It controls Celltrion, which also controls Celltrion Pharm. With expectations for biosimilars high in South Korea, his Celltrion has become a favorite among investors. share . Instead of a Chinese restaurant, Seo and his six junior … Celltrion founder Seo Jung-jin officially stepped down from the company, leaving its board on Friday. According to Celltrion, Seo has not worked as chairman since Dec. 31, following an earlier promise that he would wrap up his stint at the company by the end of 2020. The second-richest man in South Korea, Seo Jung-jin, is a striking example – he’s the billionaire co-founder behind Celltrion, the country’s most … "However, I think I will be partially involved in the company's business related to COVID-19.". save. 4:02. Once completed the firm will boast 310,000 L of cell culture capacity. Biotech boss Mr Seo Jung-jin's aim: A Covid-19-free S. Korea by next spring Celltrion chairman Seo Jung-jin said that during a pandemic crisis, pharmaceutical companies must serve as … Fullscreen. Who will lead Celltrion after Seo Jung-jin? A native of Cheongju, South Korea, Mr. Seo established Nexol Biotech, which later became Celltrion, after building his career at Samsung Electro-Mechanics, Korea Productivity Center, and Daewoo Motors. A … Chungcheongbuk-do 28117 Further details have not been divulged. He keeps the remaining 11.2 percent stake in Celltrion Healthcare. After the establishment of Celltrion Healthcare Holdings, Seo fully owns it and gave his 24.3 percent stake in Celltrion Healthcare to the new firm. PyeongChang Peace Forum Covid-19, Seo Jung-jin cofounder of Celltrion. Share. Biography of Jung-Jin Seo Currently, Jung-Jin Seo occupies the position of Chairman at Celltrion Healthcare Co., Ltd., Chairman for Celltrion, Inc., Chairman for Celltrion Pharm Inc. (a subsidiary of Celltrion, Inc.) and Chief Executive Officer at Celltrion Holdings Co., Ltd. Mr. Seo is also on the board of Korea National Opera. 0:00. Why is Korean entertainment scene flooded with audition programs? level 1. Celltrion Optimism that new testing kits and treatments developed by Celltrion can help to bring the coronavirus pandemic under control is boosting the … In … Hanjin Group chairman Cho Won-tae also saw the value of his stock holdings rise 100.6 percent from 154.2 billion won to 309.4 billion won. Seo Jung-jin is CEO of Celltrion, a biopharmaceutical company which develops drugs to treat cancer, influenza and rheumatoid arthritis, among others. Celltrion’s board welcomes the founders’ sons . Invest in CellTrion, The World's Number 1 Pharmaceutical Company. Along with the treatment, Seo said Celltrion is "ready" to jump into COVID-19 vaccine development, but will do so only when other Korean vaccine companies face difficulties in coming up with vaccines to combat coronavirus variants. Seo Jung-jin, chairman of Celltrion enjoyed the largest increase. Celltrion CEO and Vice Chairman Kee Woo-sung's current term will end in March 2023, while Celltrion Healthcare CEO Kim Hyoung-ki and Celltrion Pharm CEO Seo Jung-su will see their terms expiring in March 2022. Seo Jung-Jin is CEO and cofounder of biotech firm Celltrion, which specializes in “biosimilars” — affordable generic versions of biological products that replicate natural substances in the human body, such as antibodies. Oct. 2001 Signed the MOU on the creation of a joint venture company We have breakthroughs in Cancer treatment and cure and in many other areas, unlike no other Company. During the period, the value of Seo's stock holdings increased by 3.144 trillion won (116.4 percent) to 5.845 trillion won from 2.701 trillion won. Questions remain, however, whether this will change due to the group's plan to merge those three companies into a single entity. For this, Seo established Celltrion Healthcare Holdings for a smooth merger of the firms. Celltrion Pharm markets its products worldwide. After Celltrion Chairman Seo Jung-jin stepped down from his post at the biopharmaceutical giant, attention is being paid to the future shape of the company's leadership. Report Save. Celltrion Group was among the first that have embarked on the development of a therapeutic antibody treatment and a diagnostic kit on the onset of the global spread of the novel coronavirus, in a bid to contribute to stopping what would escalate into the coronavirus pandemic. Reply. Now he’s the second-richest person in South Korea, trailing just Samsung Electronics Co.’s chairman. Korea, Republic of (South). Hankook Ilbo photo by Wang Tae-seog. We did not know our business would have this much impact. Currently, Seo's first son, Jin-seok, is executive vice president of Celltrion, and his second son Jun-seok is a director of the company. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Now he’s the second-richest person in South Korea, trailing just Samsung Electronics Co.’s chairman. Meanwhile, Seo held an online press conference Thursday and said the company's COVID-19 treatment, Regkirona, was effective in treating a number of variants of the coronavirus including one originated from the U.K., but its efficacy was reduced in treating the South African variant. Analysts said Celltrion Group opted to set up a holding firm with Celltrion Healthcare taking a central role mostly because of expected tax benefits for Seo and fairer valuation of each company in the merger process. After Celltrion Chairman Seo Jung-jin stepped down from his post at the biopharmaceutical giant, attention is being paid to the future shape of the company's leadership. Regarding the production capacity of Regkirona, Seo said the company produced 300,000 doses for 100,000 people last year and will be able to produce up vials for 3.2 million people annually. “Chairman Seo Jung-jin announced that Celltrion is planning to construct a third factory in Korea capable of producing 120,000 liters of drugs,” a Celltrion spokesperson told this publication. Original Poster 4 minutes ago. He said that the company aims to commercialize the kit within three months with a local partner. Celltrion Healthcare was directly controlled by Seo with his 35.5 percent stake in it. Meanwhile, Celltrion founder Seo Jung Jin’s two sons have reportedly joined the company’s board of non-listed holding entities. Currently, the CEOs at Celltrion's major affiliates have their terms remaining. One was Celltrion Holdings in which Seo has a 95.5 percent stake. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Jung-Jin Seo is Former Chairman at Celltrion Pharm Inc. See Jung-Jin Seo's compensation, career history, education, & memberships. Of them, Jin-seok is also a board member of Celltrion Healthcare Holdings, raising expectations that he will likely be a board member after the two holding firms are merged. During a local investment forum in October, the Celltrion founder said he would start a venture company on "ubiquitous healthcare," an emerging area of medical technology. best. Email. According to Celltrion, Seo has not worked as chairman since Dec. 31, following an earlier promise that he would wrap up his stint at the company by the end of 2020. Before the plan, there were two main streams in Celltrion Group's shareholding structure. To counter this, Seo said the company has secured a pool of antibody candidates that can be used as a cocktail treatment with Regkirona. The dawn of legendary boldness and creativity Jung-Jin Seo, the company chairman, first founded Nexol in 2000 to examine diverse business opportunities. On Sept. 25, Celltrion announced its plan to merge the three firms to address unfair intra-affiliate trading issues and improve shareholders' value. In January, Celltrion Chairman Seo Jung-jin forecast the company would lay out $33.6 billion on its pharma business over the next decade. Seo Jung-jin, Celltrion’s Chairman, shared on a YouTube live stream on Thursday the group’s ongoing efforts on the coronavirus cure development. Celltrion Pharm Inc. operates as a pharmaceutical company. 'Super Pink Moon' shines across the world. Log in or sign up to leave a comment Log In Sign Up. In a press conference in January 2019, Chairman Seo said he asked his eldest son to be the board chairman of Celltrion. According to Celltrion, Seo has not worked as chairman since Dec. 31, following an earlier promise that he would wrap up his stint at the company by the end of 2020. Celltrion’s Chairman Seo Jung-jin speaks at a press conference held on Jan. 4 at Conrad Hotel in Yeouido, Seoul. What frustrated Celltrion founder Seo Jung-jin 16 years ago was the lack of ambition he saw in his younger coworkers at the now-defunct Daewoo Motors. He cofounded the company in 2002 and took it public in 2008. "I will pass over all my duties to executives at the annual general meetings," Seo said during an online press conference Thursday.